Fulgent Genetics, Inc. (FLGT) Tops Q1 EPS by 73c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Fulgent Genetics Reports Record First Quarter Financial Results
May 6, 2021 4:05 PM EDTFirst Quarter 2021 Results:
Record Revenue of $359.4 million, growing more than 4,500% year-over-year Record Billable tests delivered approximately 3.8 million, or 290 times the volume of first quarter of 2020 Gross Margin improved approximately 32 percentage points year-over-year NGS Revenue grew 115% year-over-year Record GAAP income of $200.7 million, or $6.52 per share Record Non-GAAP income of $202.9 million, or $6.59 per share Record Adjusted EBITDA of $271.9 million Cash from operations of $233.2 million; Cash and investments of $697.4 million as of March 31, 20212021 Outlook:
Raises full year total revenue outlook to $830 million from $800 million,... More